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A B S T R A C T
Primary intraabdominal malignant mesenchymal tumors are very rare. There are just few cases of intraabdominal
visceral malignant fibrous histiocytoma in the literature. We report a case of primary malignant fibrous histiocytoma of
the spleen in a 57-year-old man, with a recurrence eight years after the splenectomy. After the initial surgery the patient
was without complaints, and refused to receive chemotherapy or radiotherapy. Eight years after the surgery the patient
reported due to general weakness and malaise when the diagnosis of disease relapse was established. Radical surgery
was performed although the tumor involved large curvature of the stomach, left crus of the diaphragm, splenic flexure of
the colon and tail of pancreas. Four months after the surgery patient died. To the best of our knowledge, to date, only 18
cases have been reported in the literature, describing malignant fibrous histiocytoma of the spleen.
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Introduction
Malignant fibrous histiocytoma (MFH) is distinct and
pleomorphic form of sarcoma which was originally de-
scribed by Ozellio 19631 and was established by O’Brien
and Stout 19642. It usually affects soft tissue, especially
the extremities and retroperitoneum2. MFH can be
found in heart3, brain4, bones5, larynx6, lung7, kidney8,
breast9, eye10, spermatic cord11, and even aorta12. Case
with multiple synchronous primary sites of myxoid MFH
has also been described13. It most commonly occurs in
the fifth to seventh decade of life, but can be found even
in the children4,14. About 30–40% of patients with MFH
develop distant metastases, with the most common site
being the lung13. Metastatic disease in the absence of
lung metastases is highly unusual13.
Primary intra-abdominal MFH is a very rare disease,
and few cases are reported in English literature14–34.
Splenic location is very rare according to the few case re-
ports, which have been published. Since the first des-
cription of MFH of the spleen by Govoni et al. only 18
cases have been reported in the literature14–31.
Because it is such a rare tumor, little is known about
the optimal therapy. Here we report a case of local recur-
rence of the MFH of the spleen, eight years after the
splenectomy, treated with radical surgery.
Case Report
A 57-year-old man was referred to the hospital be-
cause of anorexia associated with a weight loss of 10 kg,
abdominal pain, weakness and dizziness. Eight years be-
fore splenectomy was performed in the local hospital be-
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cause of tumor of the spleen. At that time pathohis-
tological diagnosis was based on haematoxylin-eosin
staining only and finding was consistent with leiomyo-
sarcoma. After the splenectomy the patient was without
complaints and refused to receive chemotherapy or ra-
diotherapy. On physical examination, weak, poorly nour-
ished, in mild distress, afebrile and his vital signs were
all well within normal limits. Abdomen was soft, non-
-tender and painful in left upper quadrant. Bowel sounds
were presented. Microcytic anemia was found in blood
analysis (erythrocyte: 2.22 x 1012/L, normal range: 4.4–
5.7 x 1012/L; hemoglobin: 52 mmol/L, normal range:
138–175 mmol/L; hematocrit 0.163 L/L, normal range:
0.415–0.530 L/L; MCV: 73.2 fL, normal range: 86–100
fL). Serum levels of carcinoembryonic antigen (CEA), al-
pha-fetoprotein (AFP) and carbohydrate antigen 19–9
(CA 19–9) were within normal limits. Gastroduodenosco-
py was performed and showed rigid tumor on the large
curvature of the stomach. Multislice computed tomogra-
phy of abdomen showed a large solitary tumor (15 cm x
11 cm) in the left upper abdomen, relating to large curva-
ture of the stomach, left crus of the diaphragm, splenic
flexure of colon and pancreatic tail (Fig. 1a). None of the
imaging examinations showed findings in the lungs, liver
or retroperitoneum.
At laparotomy a large solitary mass (20 cm in the di-
ameter) in the left upper abdomen was noted, relating to
an upper part of a large curvature of the stomach, left
crus of the diaphragm, splenic flexure of colon and pan-
creatic tail. Macroscopically there were no intra-abdomi-
nal metastasis and un-block resection of the tumor was
performed (Fig. 1b). Gastrectomy, partial resection of the
left crus of diaphragm, distal pancreatectomy and left
hemicolectomy were performed.
Gross exanimation revealed solid, gray-white firm tu-
mor, measuring 20 cm x 18 cm x 11 cm. Microscopically
the tumor was composed of spindle cells arranged in
short cellular fascicles showing a storiform pattern with
occasional giant multinucleated cells. The mitotic rate
was moderate. Chronic inflammatory cells were scat-
tered sparsely throughout the tumor (Fig. 1c). Immuno-
histochemically tumor cells expressed CD68 (Fig. 1d) and
were negative for desmin, SMA, EMA, CD117 and S-100.
In summary, the diagnosis of malignant fibrous histio-
cytoma was made. Paraffin embedded tissue blocks ob-
tained on the previous operation were reexamined and
identical morphological and antigenic characteristics
were confirmed. Finding was in accordance with diagno-
sis of MFH, storiform-pleomorphic subtype. During the
early postoperative period patient had a left subphrenic
abscess which was treated by several ultrasound guided
punctions. After seven weeks of hospitalization patient
was discharged in good condition. For months after the
surgery the patient died.
Discussion
Malignant fibrous histiocytoma is a sarcoma of me-
senchymal origin, accounts over 30% of all soft tissue
sarcomas13,35,36. The major locations of MFH are the deep
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Fig. 1. (a) Abdominal CT: large solitary tumor in the left upper abdomen. (b) Un-block resection of the tumor. (c) Pathological findings:
tumor is composed of spindle cells arranged in short fascicles and pleomorphic multinuclear cells. Chronic inflammatory cells are
scattered throughout tumor (HEx100). (d) Tumor cells retain immunoractive for CD68 antibody (IHCx400).
tissue of the extremities, trunk and retroperito-
neum2,11,16,21. It very rarely affects intraperitoneal or-
gans11,13–35. Men are affected more frequently than wo-
men14,6,35. The incidence of MFH increases with age, with
the majority of patients being over 50 years of age13,14,35.
The local recurrence rate for MFH is 28–51%13,37,38. The
rate of distant metastasis varies from 30 to 46%37,38.The
most common site of distant metastasis was by far the
lung (63–91%), followed by lymph nodes (10%) and bone
(3–8%), taken as a proportion of all metastatic si-
tes13,37,38.
A number of prognostic factors have been examined
in terms of their predictive significance for overall sur-
vival and recurrence in MFH by various investigators, in
an attempt to better define different prognostic variables
in this diverse group of soft tissue sarcomas. The mode of
presentation of MFH depends on the primary site of the
body affected by the tumor. The final diagnosis is based
on the patohistologycal examination which rely on sev-
eral criteria, such as presence of typical spindle and po-
lygonal cells arranged in a storiform pattern, multinu-
cleated giant cells39,40 and immunohistochemical reacti-
vity41,42. There are five subtypes of MFH according to
histology: storiform-pleomorphic, myxoid, giant cell, in-
flammatory, angiomatoid36. MFH is an aggressive tumor
(giant cell has the worst prognosis) with a high potential
of metastasis to the other parts of the body, especially to
the lung, approximately 2/3 of the patients develop lung
metastasis36,37. Factors that are believed to favorably in-
fluence recurrence rates and metastasis in myxoid MFH
include: small size, superficial location, increased propor-
tion of the myxoid component and low grade13,36–38.
Advances in various techniques of chromosomal anal-
ysis have prompted many investigators to try and define
MFH on a more basic molecular level. Several candidate
genes implicated in the pathogenesis of MFH have been
recently identified43–47.
All reports support the thought that MFH indeed is a
very rare tumor and might not be the most common soft
tissue sarcoma. Intra-abdominal localization is very rare.
This is supported by only 18 cases of MFH of the spleen,
which have been reported in the world literature as far as
we know14–31. They included 10 men and 8 women. Pa-
tients’ ages range s from 11 to 82 years, predominantly
in the fourth or fifth decade of life. All tumors were lo-
cated in spleen. Two patients had another tumor located
in liver16,22. One patient had a chronic myelogenous leu-
kemia; the neoplasms were synchronous in their onset
and evolution21. All tumors were large with an average
diameter of 12 cm. The presenting symptoms are usually
nonspecific, such as general fatigue, weight loss, fever,
and abdominal pain. Spontaneous rupture of the tumor
within spleen has been reported in one case31. The most
common histologic subtype are inflammatory and pleo-
morphic subtype. All patients were treated by surgery,
excluding one autopsy case24. Because it is very rare con-
dition survival rate is unknown, there are reports from 6
to 34 months, and only difference is in our case, where
the patient died 100 months after the surgery.
The treatment for MFH is early and radical surgical
excision with resection of regional lymph nodes35. De-
spite radical excision of the tumor with free resection
margins recurrence of the tumor or metastasis are not
uncommon, especially with high grade tumor36. Local re-
currence is mainly dependent on the quality of surgical
margins, this is most important factor for a metasta-
sis-free and overall survival. Treatment for metastatic
disease or recurrence of MFH is also surgical where it is
possible48. The effectiveness of adjuvant chemotherapy
remains unclear. Some studies suggest that there is no
improvement of chemotherapy or adjuvant radiotherapy
in overall survival of the MFH patients49. This patient
did not receive any adjuvant therapy, and after surgery
had survival period of 100 months.
Conclusion
Primary MFH of the spleen are extremely rare so
there are no adequate data base for making a evidence
based treating protocol. Despite this problem we recom-
mend a radical surgical resection with a radical regional
lymphadenectomy. In case of metastases, adjuvant che-
motherapy can be considered in selected cases, but whe-
ther adjuvant therapy in this neoplasm is necessary or
useful remains unclear.
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PRIMARNI MALIGNI FIBROZNI HISTIOCITOM SLEZENE RECIDIV OSAM GODINA NAKON
SPLENEKTOMIJE
S A @ E T A K
Primarni intraabdominalni mezenhimski tumori su vrlo rijetki. U literaturi postoji svega nekoliko opisanih slu~aje-
va malignog fibroznog histiocitoma koji zahva}a visceralne intraabdominalne organe. Prikazujemo slu~aj 57-godi{njeg
bolesnika sa primarnim malignim fibroznim histiocitomom slezene, te recidivom 8 godina nakon splenektomije. Nakon
primarne operacije bolesnik se dobro osje}ao, bio je bez tegoba, te je odbio primati kemoterapiju i radioterapiju. Osam
godina nakon operacije bolesnik se javio lije~niku zbog op}e slabosti i malaksalosti te mu je dijagnosti~kom obradom
utvr|en recidiv bolesti. U~injen je radikalni operacijski zahvat iako je proces zahvatio veliku krivinu `eluca, lijevi dio
o{ita, lijenalnu fleksuru debelog crijeva i rep gu{tera~e. ^etiri mjeseca nakon operacije bolesnik je umro. Prema na{im
saznanjima, do danas je u literaturi objavljeno samo 18 slu~ajeva koji opisuju maligni fibrozni histiocitom slezene.
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